Response to Patoulias et al. letter regarding article “Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial”

Jesper Jensen*, Massar Omar, Jacob Eifer Møller, Morten Schou

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearchpeer-review

Original languageEnglish
JournalAmerican Heart Journal
Pages (from-to)106
Number of pages1
Publication statusPublished - Jun 2021

Cite this